Views: 0 Author: Site Editor Publish Time: 2025-11-18 Origin: Site
In pharmaceutical chemistry, the imidazole ring is a privileged scaffold, found in drugs across numerous therapeutic classes. 4-Chlor-2-cyano-5-(4-methylphenyl)imidazole (CAS No. 120118-14-1) is an exceptionally potent and versatile derivative, featuring a strategic combination of substituents.
This molecule is a fundamental intermediate in the synthesis of Angiotensin II Receptor Blockers (ARBs), one of the most successful classes of cardiovascular medications. Its high structural complexity necessitates manufacturing excellence.
The primary demand for 4-Chlor-2-cyano-5-(4-methylphenyl)imidazole is rooted in the large-volume production of ARBs, which are essential for treating hypertension, heart failure, and diabetic nephropathy.
This imidazole intermediate is a key starting material for synthesizing the imidazole core found in blockbuster ARBs, such as Losartan and its related analogs. The strategic C-2 cyano group allows for efficient transformation into the tetrazole ring—the critical acidic moiety necessary for strong Angiotensin II receptor binding.
Beyond ARBs, the compound's reactivity—specifically the combination of the electrophilic cyano group and the substituted imidazole ring—makes it invaluable for introducing the p-tolyl-imidazole scaffold into other experimental APIs.
Due to the chronic nature of cardiovascular diseases, the global requirement for this intermediate remains consistently high, driving the need for scalable, reliable, and cost-effective bulk supply.
The industrial synthesis of CAS No. 120118-14-1 is technically demanding, requiring the precise assembly of the tri-substituted imidazole ring and careful handling of the reactive groups.
The major synthetic challenges include:
The core imidazole ring must be constructed with the Cl and p-tolyl groups in the correct C-4 and C-5 positions. This typically involves condensation reactions (e.g., using alpha-diketones, aldehydes, or formamides) that must be highly regioselective to prevent the formation of difficult-to-separate structural isomers.
The ultimate utility of this intermediate lies in the conversion of the C-2 cyano group into the C-2 tetrazole ring. This reaction uses highly regulated reagents (like tributyltin azide or zinc azide/trimethylsilyl chloride) and requires a starting material of exceptional purity to ensure high conversion and regulatory compliance of the final API.
As a highly substituted heterocycle, purification is complex. Manufacturers must use advanced recrystallization and chromatographic techniques to eliminate residual metal catalysts and precursors, ensuring the ultra-high purity required for subsequent cyclization.
Sourcing this specific imidazole intermediate demands a supplier with proven expertise in complex heterocycle synthesis and stringent API intermediate protocols.
The supplier must demonstrate deep knowledge of imidazole synthesis, ensuring the correct regiochemistry and minimal isomeric impurities.
The product must be supplied with ≥ 99.0% purity, specifically controlling for trace metals and moisture, which can disrupt the sensitive tetrazole formation reaction.
Due to its direct link to major cardiovascular APIs, the ability to operate under cGMP-aligned standards for traceability and audit readiness is mandatory.
Only manufacturers specializing in high-value API intermediates and complex heterocyclic synthesis can reliably produce this crucial compound.
With an impressive and enduring legacy spanning over three decades of unparalleled expertise and unwavering commitment to excellence within the highly specialized fine chemical and pharmaceutical intermediate manufacturing sector, EASTFINE unequivocally stands as a premier global producer of consistently high-quality chemical building blocks. Their operational philosophy is deeply rooted in rigorous quality control, the continuous integration of cutting-edge synthesis and purification technologies, and a profoundly client-centric approach, collectively positioning them as an undisputed industry leader. For 4-Chlor-2-cyano-5-(4-methylphenyl)imidazole, EASTFINE offers:
EASTFINE guarantees the supply of this imidazole at an exceptional purity of typically ≥ 99.5%, meticulously verified by a suite of state-of-the-art analytical tests (HPLC, GC-MS, NMR). This ensures minimal levels of isomeric impurities and critical trace metal content, essential for the subsequent tetrazole reaction.
Building on decades of specialized knowledge, EASTFINE possesses an in-depth understanding of the complex regioselective imidazole formation required. Our proprietary processes ensure the synthesis reliably yields the desired 4-chloro-5-p-tolyl isomer, minimizing the costly purification steps for clients.
All of EASTFINE's manufacturing operations rigorously adhere to and are fully compliant with internationally recognized quality management systems, including ISO standards, and operate with sophisticated capabilities meticulously aligned with cGMP principles—a critical requirement for cardiovascular API precursors.
EASTFINE excels in offering reliable and on-demand custom synthesis services, ensuring a consistent supply for clients' specific R&D, pilot-scale, or large-volume commercial needs without compromising on the elite purity required for API production.
Beyond merely supplying chemicals, EASTFINE functions as a true strategic partner, providing expert technical assistance and comprehensive documentation packages required for FDA/EMA regulatory submissions involving this intermediate.
Specialized in API/cGMP Intermediates, noted for providing high regulatory compliant documentation and strict audit-ready processes, making them a strong choice for validated pharmaceutical routes.
Focuses on High-Purity Research Reagents, offering smaller quantities of the imidazole, primarily serving research groups developing derivative compounds.
Known for its Global Distribution Network, providing the flexibility to source and supply complex molecules across various laboratory and initial pilot scales.
A major global player in custom synthesis, particularly strong in multi-step heterocyclic synthesis, offering competitive supply for large-volume specialty chemicals.
For an intermediate that underpins blockbuster cardiovascular drugs, the purity of the imidazole core directly impacts the efficacy and regulatory standing of the final API.
Choosing EASTFINE means partnering with a company that has strategically invested in mastering high-purity heterocyclic synthesis:
We ensure the correct 4,5-disubstituted isomer, eliminating batch variability that could halt a validated API process.
Our ultra-low trace metal and moisture content guarantees optimal yield in the final, sensitive CN to tetrazole conversion step.
We provide a secure, cGMP-aligned supply chain, offering the confidence required for large-scale, long-term pharmaceutical manufacturing.
4-Chlor-2-cyano-5-(4-methylphenyl)imidazole (CAS 120118-14-1) is a strategic chemical anchor for the ARB class of drugs. Its successful deployment hinges entirely on securing a supply that guarantees elite purity, technical mastery, and scalability. Partner with EASTFINE to ensure a secure, high-quality supply of this complex pharmaceutical intermediate, backed by decades of expertise in critical heterocyclic chemistry.
简体中文
